MX2023006514A - Construcciones heterodimericas de fc de iga y metodos de uso de estas. - Google Patents

Construcciones heterodimericas de fc de iga y metodos de uso de estas.

Info

Publication number
MX2023006514A
MX2023006514A MX2023006514A MX2023006514A MX2023006514A MX 2023006514 A MX2023006514 A MX 2023006514A MX 2023006514 A MX2023006514 A MX 2023006514A MX 2023006514 A MX2023006514 A MX 2023006514A MX 2023006514 A MX2023006514 A MX 2023006514A
Authority
MX
Mexico
Prior art keywords
iga
constructs
hetfc
heterodimeric
methods
Prior art date
Application number
MX2023006514A
Other languages
English (en)
Inventor
Surjit Bhimarao Dixit
Eric Escobar-Cabrera
Von Kreudenstein Thomas Spreter
Florian Heinkel
Meghan Marie Verstraete
Original Assignee
Zymeworks Bc Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymeworks Bc Inc filed Critical Zymeworks Bc Inc
Publication of MX2023006514A publication Critical patent/MX2023006514A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Catalysts (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Construcciones heterodiméricas de Fc de IgA (HetFc de IgA) que comprenden una o más mutaciones de aminoácidos en el dominio CH3 que permiten la formación de una Fc heterodimérica con termoestabilidad y pureza alta. Las construcciones de HetFc de IgA pueden comprender uno o más dominios de unión a la diana. Se pueden preparar multímeros de HetFc de IgA de orden superior que comprendan múltiples construcciones de HetFc de IgA donde dos de las construcciones de HetFc de IgA estén unidas por una cadena J.
MX2023006514A 2020-12-03 2021-12-03 Construcciones heterodimericas de fc de iga y metodos de uso de estas. MX2023006514A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063121180P 2020-12-03 2020-12-03
US202163194828P 2021-05-28 2021-05-28
PCT/CA2021/051732 WO2022115963A1 (en) 2020-12-03 2021-12-03 Heterodimeric iga fc constructs and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2023006514A true MX2023006514A (es) 2023-08-30

Family

ID=81852750

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006514A MX2023006514A (es) 2020-12-03 2021-12-03 Construcciones heterodimericas de fc de iga y metodos de uso de estas.

Country Status (8)

Country Link
US (1) US20240294667A9 (es)
EP (1) EP4255934A4 (es)
JP (1) JP2023552220A (es)
KR (1) KR20230128291A (es)
AU (1) AU2021392318A1 (es)
CA (1) CA3167854A1 (es)
MX (1) MX2023006514A (es)
WO (1) WO2022115963A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024185747A1 (ja) * 2023-03-03 2024-09-12 国立大学法人 東京大学 免疫グロブリン

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS59589B1 (sr) * 2010-11-05 2019-12-31 Zymeworks Inc Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu
JP6326371B2 (ja) * 2011-11-04 2018-05-16 ザイムワークス，インコーポレイテッド Ｆｃドメインにおける変異を有する安定なヘテロ二量体抗体デザイン
US10822399B2 (en) * 2014-02-10 2020-11-03 Igm Biosciences, Inc. IgA multi-specific binding molecules
CN109476763B (zh) * 2016-07-19 2023-11-07 伊班绰斯有限责任公司 双特异性蛋白质及其制备方法
WO2019204522A1 (en) * 2018-04-17 2019-10-24 Invenra Inc. Binding molecules

Also Published As

Publication number Publication date
AU2021392318A1 (en) 2023-07-20
EP4255934A1 (en) 2023-10-11
WO2022115963A1 (en) 2022-06-09
EP4255934A4 (en) 2024-10-23
KR20230128291A (ko) 2023-09-04
US20240294667A9 (en) 2024-09-05
US20240034809A1 (en) 2024-02-01
CA3167854A1 (en) 2022-06-09
JP2023552220A (ja) 2023-12-14

Similar Documents

Publication Publication Date Title
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
EP3788068A4 (en) INTERLEUKIN-15 FUSION PROTEINS AND COMPOSITIONS AND THERAPEUTIC METHODS THEREOF
MX2021006615A (es) Proteinas de union triespecificas y metodos de uso.
AU2017263237A1 (en) GDF15 fusion proteins and uses thereof
MX2022006527A (es) Construcciones polipeptidicas de union al antigeno modificadas y usos de estas.
EP3802812A4 (en) ANTI-RNA TARGETED FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
AU2018271872A1 (en) A protein binding NKG2D, CD16 and ROR1 or ROR2
EP3850004A4 (en) NATURAL KILLER CELL COMPOSITIONS AND IMMUNOTHERAPY METHODS FOR TREATMENT OF TUMORS
EP4017979A4 (en) COMPOSITIONS AND METHODS FOR MODULATING SPLICING AND PROTEIN EXPRESSION
ZA202208710B (en) Anti-vegf protein compositions and methods for producing the same
TN2018000159A1 (en) Improved tnf binders.
EP3927730A4 (en) EXPANSION OF NATURAL KILLER CELLS AND CHIMERIC ANTIGEN RECEPTOR MODIFIED CELLS
WO2020014526A3 (en) Compositions and methods related to engineered fc-antigen binding domain constructs targeted to cd38
EP3474899A4 (en) DEGRADATION OF PROTEIN 24 WITH THREE-PIECE MOTIVE (TRIM24) BY CONJUGATING TRIM24 INHIBITORS WITH E3 LIGASELIGAND AND METHOD FOR USE
MX2023006514A (es) Construcciones heterodimericas de fc de iga y metodos de uso de estas.
EP3960756A4 (en) FLAGELLIN FUSION PROTEIN AND ITS USE
EP3833751A4 (en) COMPOSITIONS AND METHODS OF GENOME MODIFYING WITH CAS12A PROTEINS
EP4069725A4 (en) INTERLEUKIN 15 FUSION PROTEINS AND PRODRUGS, AND RELATED COMPOSITIONS AND METHODS
EP3856190A4 (en) DEGRADATION OF FAK OR FAK AND ALK BY CONJUGATION OF FAK AND ALK INHIBITORS WITH E3-LIGASE LIGANDS AND METHODS OF USE
MX2021012032A (es) Composiciones y metodos para estabilizar formulaciones que contienen proteinas.
EP4045531A4 (en) METHODS AND COMPOSITIONS COMPRISING MODIFIED FAB SCAFFOLDS AND G PROTEIN FAB BINDING DOMAINS
EP3808877A3 (en) Method of enhancing copper electroplating
EP4013445A4 (en) THERAPEUTIC PROTEIN COMPOSITIONS AND METHODS
MX2021000280A (es) Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente.
MX2021000306A (es) Composiciones y métodos relacionados con constructos de dominio de unión a antígeno y fc modificados genéticamente dirigidos a ctla-4.